Takashi Ando
Takashi Ando has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Osamu Handa
Department of Gastroenterology, Kawasaki Medical School, Okayama 701-0192, Japan
2 shared publications Toshikazu Yoshikawa
Department of Cancer ImmunoCell Regulation Kyoto Prefectural University of Medicine Kyoto Japan
2 shared publications- Yuji Naito
Department of Human Immunology and Nutrition Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan
2 shared publications - Akihiro Asakawa
Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan
1 shared publication - Akio Inui
Pharmacological Department of Herbal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
1 shared publication Akira Okajima
Department of Gastroenterology Social Insurance Kyoto Hospital Koyamashimofusa‐cho 27 Kita‐ku Kyoto 603‐8151 Japan
1 shared publication
Latest Publications
- Open Access
- 18 September 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (18) , 2376
Kyoto Classification-Based Predictive Factors Associated with the Development of Gastric Cancer After Helicobacter pylori Eradication: A Prospective Multicenter Observational Study
Background/Objectives: This study aimed to identify specific endoscopic findings associated with the development of GC following successful H. pylori eradication. Methods: This prospective multicenter observational study included patients who underwent annual surveillance endoscopy after successful H. pylori eradication therapy between September 2013 and June 2019. Endoscopic findings were evaluated one year after eradication therapy and analyzed using the Kyoto Classification of Gastritis to identify factors associated with GC development. Results: A total of 465 patients were included, including 49 patients with GC and 416 patients without GC. At the initial endoscopic assessment (median, 0.96 years post-eradication), emergence of map-like redness and invisible regular arrangement of collecting venule (RAC) as independent predictors of GC (map-like redness: hazard ratio [HR], 2.561; 95% confidence interval [CI], 1.362–4.572; p = 0.003; invisible RAC: HR, 3.131; 95% CI, 1.078–9.091; p = 0.036). Patients with map-like redness or invisible RAC showed a significantly higher incidence of GC than those without map-like redness or invisible RAC (p < 0.001 and p < 0.001, respectively). Notably, map-like redness and visible RAC appeared in 13% and 28.4% of cases within the first year after eradication, respectively. Conclusions: Map-like redness and invisible RAC were identified as independent predictors of GC following H. pylori eradication and may serve as early predictive indicators, appearing within one year of successful eradication. This finding underscores the importance of early surveillance endoscopy in identifying patients at elevated risk for GC.
- 18 September 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (18) , 2376
Open AccessKyoto Classification-Based Predictive Factors Associated with the Development of Gastric Cancer After Helicobacter pylori Eradication: A Prospective Multicenter Observational Study
Background/Objectives: This study aimed to identify specific endoscopic findings associated with the development of GC following successful H. pylori eradication. Methods: This prospective multicenter observational study included patients who underwent annual surveillance endoscopy after successful H. pylori eradication therapy between September 2013 and June 2019. Endoscopic findings were evaluated one year after eradication therapy and analyzed using the Kyoto Classification of Gastritis to identify factors associated with GC development. Results: A total of 465 patients were included, including 49 patients with GC and 416 patients without GC. At the initial endoscopic assessment (median, 0.96 years post-eradication), emergence of map-like redness and invisible regular arrangement of collecting venule (RAC) as independent predictors of GC (map-like redness: hazard ratio [HR], 2.561; 95% confidence interval [CI], 1.362–4.572; p = 0.003; invisible RAC: HR, 3.131; 95% CI, 1.078–9.091; p = 0.036). Patients with map-like redness or invisible RAC showed a significantly higher incidence of GC than those without map-like redness or invisible RAC (p < 0.001 and p < 0.001, respectively). Notably, map-like redness and visible RAC appeared in 13% and 28.4% of cases within the first year after eradication, respectively. Conclusions: Map-like redness and invisible RAC were identified as independent predictors of GC following H. pylori eradication and may serve as early predictive indicators, appearing within one year of successful eradication. This finding underscores the importance of early surveillance endoscopy in identifying patients at elevated risk for GC.
- 20 November 2012
- Published by Wiley in Helicobacter
- Vol. 18 (2) , 158-164
Impact of Helicobacter pylori Eradication on Circulating Adiponectin in Humans
Background The relationship between Helicobacter pylori infection and metabolic syndrome is not well understood. Adiponectin is an adipose‐derived protein considered to play a significant role in the development of metabolic syndrome. The aim of this study was to clarify the influence of H. pylori infection on circulating adiponectin in humans. Methods In a prospective study, 456 patients underwent endoscopy and H. pylori testing. All of the 338 H. pylori ‐positive patients received eradication therapy. Treatment was successful in 241 patients. Circulating adiponectin and other metabolic parameters were measured at baseline in all patients and 12 weeks after eradication therapy in those initially positive for H. pylori. Results Circulating adiponectin levels were not different between H. pylori ‐positive and H. pylori ‐negative patients. In the group with successful eradication, levels of total adiponectin and each multimer form were significantly increased after therapy. Conversely, the levels of total adiponectin and high‐molecular‐weight adiponectin, but not middle‐molecular‐weight and low‐molecular‐weight adiponectin, were increased in the group with unsuccessful eradication after the therapy. Conclusions Eradication therapy of H. pylori increased circulating adiponectin levels in Japanese individuals and could be beneficial for preventing metabolic syndrome conditions.
- 20 November 2012
- Published by Wiley in Helicobacter
- Vol. 18 (2) , 158-164
Impact of Helicobacter pylori Eradication on Circulating Adiponectin in Humans
Background The relationship between Helicobacter pylori infection and metabolic syndrome is not well understood. Adiponectin is an adipose‐derived protein considered to play a significant role in the development of metabolic syndrome. The aim of this study was to clarify the influence of H. pylori infection on circulating adiponectin in humans. Methods In a prospective study, 456 patients underwent endoscopy and H. pylori testing. All of the 338 H. pylori ‐positive patients received eradication therapy. Treatment was successful in 241 patients. Circulating adiponectin and other metabolic parameters were measured at baseline in all patients and 12 weeks after eradication therapy in those initially positive for H. pylori. Results Circulating adiponectin levels were not different between H. pylori ‐positive and H. pylori ‐negative patients. In the group with successful eradication, levels of total adiponectin and each multimer form were significantly increased after therapy. Conversely, the levels of total adiponectin and high‐molecular‐weight adiponectin, but not middle‐molecular‐weight and low‐molecular‐weight adiponectin, were increased in the group with unsuccessful eradication after the therapy. Conclusions Eradication therapy of H. pylori increased circulating adiponectin levels in Japanese individuals and could be beneficial for preventing metabolic syndrome conditions.
- 13 October 2007
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 53 (4) , 933-937
Endoscopic Analysis of Gastric Ulcer after One Week's Treatment with Omeprazole and Rabeprazole in Relation to CYP2C19 Genotype
- 13 October 2007
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 53 (4) , 933-937
Endoscopic Analysis of Gastric Ulcer after One Week's Treatment with Omeprazole and Rabeprazole in Relation to CYP2C19 Genotype